Pyxis Oncology Inc
PYXS
查看详细走势图
1.100USD
-0.010-0.90%
交易中 （美东）报价延迟15分钟
68.36M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.90%
5天
-36.42%
1月
-79.40%
6月
-14.06%
今年开始到现在
-29.49%
1年
-31.25%
查看详细走势图
TradingKey Pyxis Oncology Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Pyxis Oncology Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名120/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.17。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Pyxis Oncology Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
买入
评级
7.175
目标均价
+71.65%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Pyxis Oncology Inc亮点
亮点风险
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
业绩增长期
公司处于发展阶段，最新年度总收入16.15M美元
估值高估
公司最新PE估值-0.70，处于3年历史高位
机构减仓
最新机构持股20.78M股，环比减少47.16%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值2.16M
Pyxis Oncology Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Pyxis Oncology Inc简介
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
公司代码PYXS
公司Pyxis Oncology Inc
CEOSullivan (Lara S)
网址https://pyxisoncology.com/
常见问题
Pyxis Oncology Inc(PYXS)的当前股价是多少？
Pyxis Oncology Inc(PYXS)的当前股价是 1.100。
Pyxis Oncology Inc的股票代码是什么？
Pyxis Oncology Inc的股票代码是PYXS。
Pyxis Oncology Inc股票的52周最高点是多少？
Pyxis Oncology Inc股票的52周最高点是5.550。
Pyxis Oncology Inc股票的52周最低点是多少？
Pyxis Oncology Inc股票的52周最低点是0.833。
Pyxis Oncology Inc的市值是多少？
Pyxis Oncology Inc的市值是68.36M。
Pyxis Oncology Inc的净利润是多少？
Pyxis Oncology Inc的净利润为-77.33M。
现在Pyxis Oncology Inc(PYXS)的股票是买入、持有还是卖出？
根据分析师评级，Pyxis Oncology Inc(PYXS)的总体评级为买入，目标价格为7.175。
Pyxis Oncology Inc(PYXS)股票的每股收益（EPS TTM）是多少
Pyxis Oncology Inc(PYXS)股票的每股收益（EPS TTM）是-1.592。
相关品种
